BioAtla (NASDAQ:BCAB) Shares Up 3.7% – Should You Buy?

BioAtla, Inc. (NASDAQ:BCAB)’s share price was up 3.7% on Friday . The stock traded as high as $3.80 and last traded at $3.68. Approximately 41,216 shares traded hands during mid-day trading, a decline of 37% from the average daily volume of 65,113 shares. The stock had previously closed at $3.55.

Analysts Set New Price Targets

Several research analysts have commented on BCAB shares. Wall Street Zen raised BioAtla to a “hold” rating in a research report on Saturday, April 11th. Weiss Ratings restated a “sell (e+)” rating on shares of BioAtla in a research note on Wednesday, June 3rd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BioAtla currently has an average rating of “Hold” and a consensus price target of $200.00.

BioAtla Stock Up 3.7%

The firm has a market cap of $6.10 million, a price-to-earnings ratio of -0.09 and a beta of 0.79. The stock has a fifty day moving average price of $4.06 and a 200-day moving average price of $11.97.

BioAtla (NASDAQ:BCAB) last released its quarterly earnings results on Friday, May 15th. The company reported ($4.22) EPS for the quarter, topping the consensus estimate of ($10.00) by $5.78.

Institutional Trading of BioAtla

Several hedge funds and other institutional investors have recently made changes to their positions in BCAB. Acadian Asset Management LLC grew its position in BioAtla by 968.9% during the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after buying an additional 1,531,994 shares during the period. Marshall Wace LLP purchased a new stake in shares of BioAtla during the 4th quarter worth approximately $508,000. Millennium Management LLC grew its holdings in shares of BioAtla by 123.4% in the 4th quarter. Millennium Management LLC now owns 762,394 shares of the company’s stock worth $433,000 after acquiring an additional 421,072 shares during the period. ADAR1 Capital Management LLC purchased a new position in BioAtla in the 4th quarter valued at approximately $104,000. Finally, Susquehanna International Group LLP raised its holdings in BioAtla by 237.6% during the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after purchasing an additional 177,760 shares during the last quarter. Institutional investors and hedge funds own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.